Astrid Lavens

Astrid Lavens

Auto-generated profile, based on publicly available information

Astrid Lavens

Health Services Research, Sciensano, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2021 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
ALAstrid Lavens
Astrid Lavens
FNFrank Nobels
Frank Nobels
Christophe De BlockChristophe De Block
Christophe De Block
POPhilippe Oriot
Philippe Oriot
AVAnn Verhaegen
Ann Verhaegen
CMChantal Mathieu
Chantal Mathieu
Objective: Achieving good metabolic control in people with type 1 diabetes (T1D) remains a challenge, despite the evolutions in diabetes technologies over the past decade. Here we investigate the evolution of metabolic control in people with T1D, where care is provided by specialized centers with access to technology, diabetes education, and regular follow-up. Methods: Data were cross-sectionally collected between 2010 and 2018 from more than 100 centers in Belgium. The evolutions over time of hemoglobin A1C (HbA1c), low-density lipoprotein (LDL) cholesterol, and systolic blood pressure (SBP) were investigated, together with the evolutions of use of insulin pump (continuous subcutaneous insulin infusion [CSII]), continuous glucose monitoring (CGM), and lipid-lowering and antihypertensive drugs. Association of HbA1c with gender, age, diabetes duration, and technology use was analyzed on the most recent cohort. Results: The study population contained data from 89,834 people with T1D (age 1–80 years). Mean HbA1c decreased from 65 mmol/mol (8.1%) in 2010–2011 to 61 mmol/mol (7.7%) in 2017–2018 ( P < 0.0001, adjusted for gender, age, diabetes duration, and technology use). Respectively, mean LDL cholesterol decreased from 2.45 mmol/L (94.6 mg/dL) to 2.29 mmol/L (88.5 mg/dL) ( P < 0.0001, adjusted for gender, age, and diabetes duration), and mean SBP remained stable. CGM usage increased, whereas the use of CSII and lipid-lowering and antihypertensive drugs remained stable. Gender, age, diabetes duration, and technology use were independently associated with HbA1c. Conclusions: Our real-world data show that metabolic and lipid control improved over time in a system where T1D care is organized through specialized multidisciplinary centers with emphasis on linking education to provision of technology, and its quality is monitored.

13 September 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
ALAstrid Lavens
Astrid Lavens
Christophe De BlockChristophe De Block
Christophe De Block
POPhilippe Oriot
Philippe Oriot
LCLaurent Crenier
Laurent Crenier
JPJean-Christophe Philips
Jean-Christophe Philips
OEon behalf of the IQED Group of Experts
on behalf of the IQED Group of Experts
Aims/hypothesis Metabolic abnormalities such as central obesity, insulin resistance, dyslipidaemia and hypertension, often referred to as ‘the metabolic syndrome’ (or ‘combined metabolic abnormalities’), are increasingly being identified in people living with type 1 diabetes, accelerating the risk for CVD. As a result, in recent years, treatment in people living with type 1 diabetes has shifted to improving overall metabolic health rather than glucose control alone. In Belgium, diabetes care for people living with type 1 diabetes is centrally organised. The Initiative for Quality Improvement and Epidemiology in Diabetes, imposed by the Belgian health insurance system, has systematically collected data from patients on intensive insulin therapy treated in all 101 diabetes clinics in Belgium since 2001. The aim of this real-world study is to describe the evolution of treatment and metabolic health, including the prevalence of obesity and combined metabolic abnormalities, in people living with type 1 diabetes over the past 20 years, and to compare the treatment and prevalence of complications between those with and without combined metabolic abnormalities. Methods We analysed data on adults (≥16 years old) living with type 1 diabetes, who were diagnosed at age ≤45 years and who had a diabetes duration ≥1 year, collected between 2001 and 2022. The evolution of HbA1c, BMI, LDL-cholesterol, systolic BP, lipid-lowering therapy and antihypertensive therapy over time was analysed. The prevalence of individual and multiple metabolic abnormalities according to various definitions of the metabolic syndrome/combined metabolic abnormalities was analysed, and the association between combined metabolic abnormalities and metabolic health indicators, complications and treatment was investigated in the 2022 data. Results The final dataset consisted of 26,791 registrations of adults living with type 1 diabetes collected between 2001 and 2022. Although glycaemic and lipid control generally improved over time, the prevalence of obesity strongly increased (12.1% in 2001 vs 21.7% in 2022, p<0.0001), as did the presence of combined metabolic abnormalities (WHO criteria: 26.9% in 2001 vs 42.9% in 2022 in women, p<0.0001; 30.4% in 2001 vs 52.1% in 2022 in men, p<0.0001; WHO criteria without albuminuria: 22.3% in 2001 vs 40.6% in 2022 in women, p<0.0001; 25.1% in 2001 vs 49.2% in 2022 in men, p<0.0001; NCEP-ATPIII criteria: 39.9% in 2005 vs 57.2% in 2022 in women, p<0.0001; 40.8% in 2005 vs 60.9% in 2022 in men, p<0.0001; IDF criteria: 43.9% in 2005 vs 59.3% in 2022 in women, p58 mmol in women: 53.3% vs 41.1%, p<0.0001). People with combined metabolic abnormalities were more often treated with adjunct therapies such as metformin, sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists. In both men and women, the presence of combined metabolic abnormalities was strongly related to the presence of eye complications, peripheral neuropathy, chronic kidney disease and CVD, corrected for age, diabetes duration and HbA1c. Conclusions/interpretation Overweight, obesity and combined metabolic abnormalities are increasingly being identified in people living with type 1 diabetes, further accelerating the risk of microvascular and macrovascular complications. Early identification of the presence of combined metabolic abnormalities should enable therapeutic interventions to be modified towards multifactorial approaches, with attention to education on avoidance of overweight (e.g. dietary counselling) in addition to strict glycaemic control and intensification of use of antihypertensive agents and statins. Use of adjunct therapies in this population as a tool should be explored more thoroughly to reduce risk of complications. Graphical Abstract

28 August 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
ALAstrid Lavens
Astrid Lavens
Christophe De BlockChristophe De Block
Christophe De Block
POPhilippe Oriot
Philippe Oriot
JPJean-Christophe Philips
Jean-Christophe Philips
MVMichel Vandenbroucke
Michel Vandenbroucke
BIBelgian Group of Experts IQED
Belgian Group of Experts IQED
Aims: This study investigates the impact of the era of diabetes onset on the prevalence of diabetic retinopathy and albuminuria 15 years post‐diagnosis in people living with type 1 diabetes (T1D) within a national healthcare system offering structured multidisciplinary endocrinology care. Materials and Methods: We analysed data of 2176 individuals diagnosed with T1D before age 30, comparing two cohorts based on diabetes onset period: group A (1985–1998) and group B (1998–2009). The prevalence of diabetic retinopathy and albuminuria was assessed using generalised estimating equations. Results: Glycaemic control (haemoglobin A1C: 8.3% vs. 8.1%, p < 0.0001) and low density lipoprotein cholesterol (2.6 mmol/L vs. 2.5 mmol/L, p < 0.001) were poorer in group A, whereas obesity prevalence was higher in group B (12.8% vs. 17.4%, p < 0.01). Group A used more antihypertensive therapy (14.9% vs. 11.5%, p < 0.01), while group B used more lipid‐lowering therapy (9.2% vs. 15.9%, p < 0.0001). The prevalence of diabetic retinopathy 15 years post‐diagnosis significantly declined from 36.3% in 2001 to 21.1% in 2022 ( p < 0.0001). This decrease was particularly pronounced in individuals with diabetes onset after 11 years of age. The prevalence of albuminuria, adjusted for age and sex, decreased from 14.9% in 2001 to 7.3% in 2022 ( p < 0.05). Conclusions: Individuals diagnosed with T1D after 1998 had fewer microvascular complications 15 years post‐diagnosis, especially less retinopathy in those with diabetes onset after age 11. This decline highlights the impact of improved care.

2 June 2026 in BMC Public Health
Verified
Journal Article
Open access
ALA. Lavens
A. Lavens
DJD. Jaminé
D. Jaminé
MUM. Urbina
M. Urbina
BVBert Vaes
Bert Vaes
CMC. Mathieu
C. Mathieu
CLCatherine Lucet
Catherine Lucet
Background: Diabetes is a highly prevalent non-communicable disease with a growing global burden, posing significant challenges to healthcare systems. Effective management requires comprehensive monitoring of prevalence, risk factors, and outcomes across diverse diabetes populations. While several European countries have established or are establishing national diabetes registries to guide care and policy, Belgium’s diabetes data landscape remains fragmented, lacking a unified national diabetes registry. Existing datasets cover limited populations and care settings, hindering a complete understanding of diabetes care and prevalence. To address this, the Belgian Diabetes Forum initiated the Diabetes Data Cell Project , aiming to integrate multiple healthcare datasets and create a comprehensive national diabetes registry. Methods: An inventory of existing databases was compiled, and the quality of the datasets was assessed based on predefined criteria. A selection of core datasets was made to ensure reliable identification of individuals with diabetes, based on clinical diagnoses and coverage of the entire healthcare spectrum. Complementary datasets were selected to enrich the core datasets with additional information on healthcare utilization and mortality. All datasets had to allow for linkage at the individual level and provide longitudinal data. Results: We identified two large core datasets of people with diabetes who are treated in primary care and in hospital outpatient clinics. We obtained permission from the Information Security Commission to link both sets for the period 2017–2027 at the individual level to the national insurance dataset — where all medical procedures are recorded. That insurance dataset is also linked to mortality data. The first data extraction, covering 2017–2024, resulted in a linked dataset of 76 964 unique individuals. The combined dataset provides a comprehensive overview of diabetes diagnosis and type, diabetes duration, demographic characteristics, clinical outcomes, laboratory results, medications and other treatments, medical procedures and hospitalizations, complications, healthcare utilization, mortality and costs of care. Conclusions: This study demonstrates that large-scale linkage of Belgian health data is feasible within the current legal and technical framework and enables the identification of people living with diabetes across both primary and specialized care. By integrating clinical and administrative datasets at the individual level, the project provides a comprehensive and longitudinal view of diabetes care, supporting analyses of treatment patterns, care processes, outcomes, and healthcare utilization. This work lays the foundation for a continuously updated, ‘ living’ national diabetes registry in Belgium and represents an important step towards more integrated, data-driven healthcare policy.

2 July 2026 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
ALAstrid Lavens
Astrid Lavens
JPJean-Christophe Philips
Jean-Christophe Philips
CBChristophe De Block
Christophe De Block
LCLaurent Crenier
Laurent Crenier
POPhilippe Oriot
Philippe Oriot
CMChantal Mathieu
Chantal Mathieu
Objective: To evaluate long-term trends in metabolic outcomes among people living with type 1 diabetes (T1D) within a nationwide structured care program in Belgium with full reimbursement of diabetes technologies. Methods: Repeated cross-sectional analyses were performed across three audit periods (2010–2011, 2017–2018, and 2023–2024). Outcomes included glycated hemoglobin (HbA1c), low-density lipoprotein (LDL) cholesterol, systolic blood pressure (SBP), and body mass index. Trends were analyzed using generalized estimating equations adjusted for age, sex, diabetes duration, insulin delivery, and glucose monitoring modalities. In 2023–2024, glycemic outcomes were compared across technology use, including hybrid closed-loop (HCL) therapy. Results: In adults, HbA1c decreased from 7.9% (62.8 mmol/mol) to 7.5% (58.5 mmol/mol, P < 0.001), with target attainment (<7%; <53 mmol/mol) increasing from 22.3% to 35.1%. In children and adolescents, HbA1c declined from 8.0% (63.5 mmol/mol) to 7.6% (59.0 mmol/mol, P < 0.01), and target attainment rose from 19.7% to 33.1% ( P < 0.001). Continuous glucose monitoring (CGM) exceeded 90% by 2023–2024, while insulin pump use reached 25% in adults and 47% in younger individuals. In adults, HCL therapy was associated with lower HbA1c (7.0%; 53.5 mmol/mol), higher time-in-range (73%), and lower time-below-range (1.5%) compared with other modalities ( P < 0.001). LDL cholesterol improved, with target attainment (<70 mg/dL; <1.8 mmol/L) increasing from 18.3% to 37.4% ( P < 0.001), and from 15.5% to 46.5% among those with cardiovascular disease (<55 mg/dL; <1.4 mmol/L, P < 0.001). SBP remained stable. Obesity prevalence increased in all age groups. Conclusions: Over 14 years, glycemic and lipid outcomes improved alongside near-universal CGM use and increasing adoption of HCL therapy. However, rising obesity and persistent smoking-related risks highlight the need for targeted prevention strategies. These real-world data confirm that benefits seen in clinical trials translate into durable population-level improvements and support integrated care models for implementing diabetes technology effectively.